73663-82-8

Usage

InChI:InChI=1/C9H10INO/c1-7-4-2-3-5-8(7)11-9(12)6-10/h2-5H,6H2,1H3,(H,11,12)

Upstream product

• 917-64-6 methyl magnesium iodide 
• 95-53-4 o-toluidine 
• 60-29-7 diethyl ether 
• 623-48-3 ethyl iodoacetae 
• 5332-69-4 2-bromo-N-(2'-methylphenyl)acetamide 
• 105-39-5 chloroacetic acid ethyl ester 
• 37394-93-7 2-chloro-N-(2-methylphenyl)acetamide 

Downstream Products

• 302542-40-1 2-(Pyrazol-1-yl) 2'-methylacetanilide 
• 302542-42-3 2-(4-iodo-3,5-dimethyl-pyrazol-1-yl)-N-o-tolyl-acetamide 
• 302542-44-5 2-(3,5-dimethyl-4-nitro-pyrazol-1-yl)-N-o-tolyl-acetamide 
• 79686-26-3 2-[N-(2-tolyl)carbamoylmethyl)thio-4,6-dimethyl-5-bromopyrimidine 
• 76810-18-9 4-Oxy-1-o-tolyl-1H-pyrazin-2-one 
• 76809-99-9 2-hydroxylamino-N-(2-methylphenyl)acetamide 
• 76809-78-4 C₁₆H₁₆N₂O₂ 

Relevant academic research and scientific papers

Design and synthesis of novel 4'-demethyl-4-deoxypodophyllotoxin derivatives as potential anticancer agents

A group of podophyllotoxin (PPT) derivatives (7a-j) were synthesized by conjugating aryloxyacetanilide moieties to the 4'-hydroxyl of 4'-demethyl-4-deoxypodophyllotoxin (DDPT), and their anticancer activity was evaluated. It was found that the most potent compound 7d inhibited the proliferation of three cancer cell lines with sub to low micromolar IC50 values. Furthermore, it was demonstrated that 7d induced cell cycle arrest in G2/M phase in MGC-803 cells, and regulated the expression of cell cycle check point proteins, such as cyclin A, cyclin B, CDK1, cdc25c, and p21. Finally, 4 mg/kg of 7d reduced the weights and volumes of HepG2 xenografts in mice. Our findings suggest that 7d might be a potential anticancer agent.

Synthesis and NMR study of 2-[N-(Aryl)carbamoylmethyl]phthalazimum iodides

2-[N-(Aryl)carbamoylmethyl]phthalazinium iodides 11b-k were obtained, for the first time, by reaction between N-aryl-2-iodoacetamides 9b-k and phthalazine (10). The parent compound 11a was prepared by quaternization of phthalazine with iodoacetamide. The structure of the quaternary salts 11a-k was investigated by NMR experiments, namely HH-COSY, 1H- 13C-COSY and NOE.

Pyrimidine-2-sulphides and their S-oxides for use in medicine and methods of use therefor, pharmaceutical compositions containing them, processes for their preparation and per se novel sulphides and S-oxides

Compounds of the formula STR1 (wherein X represents a halogen atom; n is 0, 1 or 2; R1 and R2, which may be the same or different, each represents a hydrogen atom or a carboxyl, esterified carboxyl, amido or mono- or di-C1-4 alkylamido group or a C1-4 alkyl group which may if desired carry a carboxyl or esterified carboxyl group; and R3 represents a C1-32 saturated or unsaturated, straight or branched, cyclic or acyclic aliphatic group or an araliphatic or heterocyclic substituted aliphatic group, a heterocyclic group or an aryl group which groups may if desired carry one or more substituents selected from halogen atoms and oxo, nitro, hydroxy, etherified hydroxy, esterified hydroxy, primary, secondary or tertiary amino, acylamino etherified mercapto or S=O or --SO2 derivatives thereof and esterified phosphonic acid groups) and, where an acidic or basic group is present, physiologically compatible salts thereof have been found to be of use in combating abnormal cell proliferation. The compounds are prepared inter alia by oxidation of the corresponding sulfide, displacement of a leaving atom or group from the 2-position of the pyrimidine by reaction with a sulfinic acid or by ring closure of the pyrimidine ring.